Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 76 to 100 of 1904

TitleReference numberPublishedLast updated
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
COVID-19 rapid guideline: managing COVID-19NG191
Artificial intelligence (AI)-derived software to help clinical decision making in strokeDG57
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessmentHTE18
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedemaIPG785
Cabozantinib with nivolumab for untreated advanced renal cell carcinomaTA964
Twin and triplet pregnancyNG137
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA963
Kurin Lock for blood culture collectionMTG77
GaitSmart rehabilitation exercise programme for gait and mobility issuesMTG78
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancerIPG784
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessmentHTE17
Ovarian cancer: identifying and managing familial and genetic riskNG241

Results per page

  1. 10
  2. 25
  3. 50
  4. All